ClinicalTrials.gg
CompletedNCT02308098BUFODILUpdated Jun 30, 2015

To Confirm Equivalent Bronchodilator Efficacy of the Test Product Compared to the Reference Product

A Phase 3 interventional study of Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh and Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh in Asthma, sponsored by Orion Corporation, Orion Pharma. Completed at 1 site in Bulgaria. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-06-30.

Sponsored by Orion Corporation, Orion Pharma · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Asthma by Orion Corporation, Orion Pharma — none open to participants now, none under way, none of them phase 3. Asthma · Orion Corporation, Orion Pharma.

Enrollment
9th of 19
72 · median 72
Started
2014
with 1 other
Phase 3
Only one
of the 21
Registered
14th of 21
by date

Among the 21 studies in Asthma by Orion Corporation, Orion Pharma, this one is the 9th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2014, is the only one in phase 3, and was the 14th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 21 studies in Asthma by Orion Corporation, Orion Pharma is open now. The open studies under Asthma, anywhere →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies in Asthma by Orion Corporation, Orion Pharma as a file.
02

Study summary

The purpose of this study is to confirm equivalent bronchodilator efficacy of the test product compared to the reference product.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main inclusion criteria:

  • Written
  • Asthma diagnosis for at least 6 months
  • Prebronchodilator 45-90% of the predicted value
  • Demonstration of reversible airway obstruction
  • Stable asthma on the same regular treatment for at least 4 weeks before the study
  • Non-smoker for at least 6 months before the study

Main exclusion criteria

  • Respiratory infection within 4 weeks before the study
  • Smoking history of more than 10 pack-years
  • Other severe chronic respiratory disease than asthma
  • Concurrent illness that would interfere with the interpretation of the study results or constitute a health risk for the patient if he/she takes part in the study
  • interval > 450 ms in males or > 470 ms in females
  • Abnormal serum potassium value or other laboratory finding
  • Systolic blood pressure over 180 mmHg and/or diastolic blood pressure over 100 mmHg
  • Treatment with a long-acting β2-agonist, a xanthine-derivative, a β-blocker or with a (other than inhaled) within 4 weeks before the study
  • Use of drugs that prolong QT-interval
  • Women who are pregnant, breast-feeding or without reliable
  • Participation in another clinical drug study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh

    Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh Placebo Symbicort Turbuhaler 320/9 ug/inhalation 4 inh

    Drug: Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh · Drug: Placebo Symbicort Turbuhaler 320/9 ug/inhalation 4 inh

  • Experimental
    Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh

    Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh Placebo Symbicort Turbuhaler 320/9 ug/inhalation 1 inh

    Drug: Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh · Drug: Placebo Symbicort Turbuhaler 320/9 ug/inhalation 1 inh

  • Experimental
    Symbicort Turbuhaler 320/9 ug/inhalation 4 inh

    Symbicort Turbuhaler 320/9 ug/inhalation 4 inh Placebo Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh

    Drug: Symbicort Turbuhaler 320/9 ug/inhalation 4 inh · Drug: Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh

  • Experimental
    Symbicort Turbuhaler 320/9 ug/inhalation 1 inh

    Symbicort Turbuhaler 320/9 ug/inhalation 1 inh Placebo Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh

    Drug: Symbicort Turbuhaler 320/9 ug/inhalation 1inh · Drug: Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh

Interventions

  • DrugBudesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh
  • DrugBudesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh
  • DrugSymbicort Turbuhaler 320/9 ug/inhalation 4 inh
  • DrugSymbicort Turbuhaler 320/9 ug/inhalation 1inh
  • DrugPlacebo Symbicort Turbuhaler 320/9 ug/inhalation 4 inh
  • DrugPlacebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh
  • DrugPlacebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh
  • DrugPlacebo Symbicort Turbuhaler 320/9 ug/inhalation 1 inh
06

What researchers measure

Primary outcomes

  1. Average FEV1

    FEV1 determined from serial spirometry and calculated on the basis of area under the curve

    Time frame: 12 h

Secondary outcomes

  1. Maximum FEV1

    Maximum FEV1 over the 12-hour serial assessments

    Time frame: 12 h

  2. FEV1 at 12 h

    FEV1 at 12 hours post-dose

    Time frame: 12 h

07

Study locations

1 site
  • Specialized Hospital for Active Treatment for Pneumophthisiatric Diseases Dr Dimitar Gramatikov-Ruse EOOD
    Ruse, Bulgaria
08

References and documents

Publications

  • Lahelma S, Vahteristo M, Metev H, Taseva M, Stamatova N, Bartha A, Schlezak J, Sairanen U. Equivalent bronchodilation with budesonide/formoterol combination via Easyhaler and Turbuhaler in patients with asthma. Respir Med. 2016 Nov;120:31-35. doi: 10.1016/j.rmed.2016.09.016. Epub 2016 Sep 25. PubMed 27817813 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2014, a primary completion of Jun 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2014
First posted
Dec 4, 2014
Start
Dec 2014
Primary completionActual
Jun 2015
CompletionActual
Jun 2015
Last update
Jun 30, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02308098
Responsible party
Sponsor
First posted
Dec 4, 2014
Start date
Dec 2014
Primary completion
Jun 2015
Completion
Jun 2015
Last update
Jun 30, 2015

Study contacts

Hristo Metev, MD
principal investigator · Specialized Hospital for Active Treatment for Pneumophthisiatric Diseases Dr Dimitar Gramatikov-Ruse EOOD

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion